These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 19808227

  • 1. Renal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition.
    Martens DH, Rake JP, Navis G, Fidler V, van Dael CM, Smit GP.
    Clin J Am Soc Nephrol; 2009 Nov; 4(11):1741-6. PubMed ID: 19808227
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study.
    Melis D, Parenti G, Gatti R, Casa RD, Parini R, Riva E, Burlina AB, Dionisi Vici C, Di Rocco M, Furlan F, Torcoletti M, Papadia F, Donati A, Benigno V, Andria G.
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):19-25. PubMed ID: 15963056
    [Abstract] [Full Text] [Related]

  • 3. Systematic review on urine albumin testing for early detection of diabetic complications.
    Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.
    Health Technol Assess; 2005 Aug; 9(30):iii-vi, xiii-163. PubMed ID: 16095545
    [Abstract] [Full Text] [Related]

  • 4. Short-term effect of captopril on microalbuminuria in children with glycogen storage disease type Ia.
    Ozen H, Ciliv G, Koçak N, Saltik IN, Yüce A, Gürakan F.
    J Inherit Metab Dis; 2000 Jul; 23(5):459-63. PubMed ID: 10947200
    [Abstract] [Full Text] [Related]

  • 5. Hyperfiltration and renal disease in glycogen storage disease, type I.
    Baker L, Dahlem S, Goldfarb S, Kern EF, Stanley CA, Egler J, Olshan JS, Heyman S.
    Kidney Int; 1989 Jun; 35(6):1345-50. PubMed ID: 2671467
    [Abstract] [Full Text] [Related]

  • 6. Renal function and kidney size in glycogen storage disease type I.
    Reitsma-Bierens WC, Smit GP, Troelstra JA.
    Pediatr Nephrol; 1992 May; 6(3):236-8. PubMed ID: 1616830
    [Abstract] [Full Text] [Related]

  • 7. Modifiable factors affecting renal preservation in type I glycogen storage disease after liver transplantation: a single-center propensity-match cohort study.
    Chan YC, Liu KM, Chen CL, Ong AD, Lin CC, Yong CC, Tsai PC, Lu LS, Wu JY.
    Orphanet J Rare Dis; 2021 Oct 11; 16(1):423. PubMed ID: 34635148
    [Abstract] [Full Text] [Related]

  • 8. Preventing end-stage renal disease.
    Mogensen CE.
    Diabet Med; 1998 Oct 11; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [Abstract] [Full Text] [Related]

  • 9. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate.
    Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, Fioretto P.
    Diabetes; 2000 Mar 11; 49(3):476-84. PubMed ID: 10868971
    [Abstract] [Full Text] [Related]

  • 10. Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.
    Okechuku GO, Shoemaker LR, Dambska M, Brown LM, Mathew J, Weinstein DA.
    J Inherit Metab Dis; 2017 Sep 11; 40(5):703-708. PubMed ID: 28612263
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of renal graft haemodynamia by 51Cr-EDTA and o-[131I]iodohippurate: its use in the early diagnosis of glomerular hyperfiltration.
    Estorch M, Tembl A, Antonijoan R, Hernandez A, Mari C, Flotats A, Camacho V, Sola R, Barbanoj M, Carrio I.
    Nucl Med Commun; 2003 Jun 11; 24(6):679-82. PubMed ID: 12766604
    [Abstract] [Full Text] [Related]

  • 12. Age-dependent enzymuria, proteinuria and changes in renal blood flow and glomerular filtration rate in rats.
    Casadevall G, Piera C, Setoain J, Queralt J.
    Mech Ageing Dev; 1995 Jul 28; 82(1):51-60. PubMed ID: 7475356
    [Abstract] [Full Text] [Related]

  • 13. Strict blood-pressure control and progression of renal failure in children.
    ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F.
    N Engl J Med; 2009 Oct 22; 361(17):1639-50. PubMed ID: 19846849
    [Abstract] [Full Text] [Related]

  • 14. Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition.
    Mulhern JG, Lipkowitz GS, Braden GL, Madden RL, O'Shea MH, Harvilchuck H, Guarnera JM, Germain MJ.
    Am J Nephrol; 1995 Oct 22; 15(4):318-22. PubMed ID: 7573190
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
    Sasongko TH, Nagalla S, Ballas SK.
    Cochrane Database Syst Rev; 2013 Mar 28; (3):CD009191. PubMed ID: 23543572
    [Abstract] [Full Text] [Related]

  • 16. Time to abandon microalbuminuria?
    Ruggenenti P, Remuzzi G.
    Kidney Int; 2006 Oct 28; 70(7):1214-22. PubMed ID: 16871239
    [Abstract] [Full Text] [Related]

  • 17. Chronic kidney disease in hypertension under specialist care: the I-DEMAND study.
    Leoncini G, Viazzi F, Rosei EA, Ambrosioni E, Costa FV, Leonetti G, Pessina AC, Trimarco B, Volpe M, Deferrari G, Pontremoli R.
    J Hypertens; 2010 Jan 28; 28(1):156-62. PubMed ID: 19915481
    [Abstract] [Full Text] [Related]

  • 18. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun 28; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 19. Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study.
    Melis D, Cozzolino M, Minopoli G, Balivo F, Parini R, Rigoldi M, Paci S, Dionisi-Vici C, Burlina A, Andria G, Parenti G.
    J Pediatr; 2015 Apr 28; 166(4):1079-82. PubMed ID: 25641239
    [Abstract] [Full Text] [Related]

  • 20. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
    Plum J, Bünten B, Németh R, Grabensee B.
    J Am Soc Nephrol; 1998 Dec 28; 9(12):2223-34. PubMed ID: 9848776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.